Guleken Zozan, Ceylan Zeynep, Aday Aynur, Bayrak Ayşe Gül, Hindilerden İpek Yönal, Nalçacı Meliha, Jakubczyk Paweł, Jakubczyk Dorota, Kula-Maximenko Monika, Depciuch Joanna
Faculty of Medicine, Department of Physiology, Gaziantep Islam Science and Technology University, Gaziantep, Turkey; Faculty of Medicine, Rzeszów University, Rzeszów, Poland.
Samsun University, Faculty of Engineering, Department of Industrial Engineering, Samsun, Turkey.
Nanomedicine. 2023 Sep;53:102706. doi: 10.1016/j.nano.2023.102706. Epub 2023 Aug 25.
Primary myelofibrosis (PM) is one of the myeloproliferative neoplasm, where stem cell-derived clonal neoplasms was noticed. Diagnosis of this disease is based on: physical examination, peripheral blood findings, bone marrow morphology, cytogenetics, and molecular markers. However, the molecular marker of PM, which is a mutation in the JAK2V617F gene, was observed also in other myeloproliferative neoplasms such as polycythemia vera and essential thrombocythemia. Therefore, there is a need to find methods that provide a marker unique to PM and allow for higher accuracy of PM diagnosis and consequently the treatment of the disease. Continuing, in this study, we used Raman spectroscopy, Principal Components Analysis (PCA), and Partial Least Squares (PLS) analysis as helpful diagnostic tools for PM. Consequently, we used serum collected from PM patients, which were classified using clinical parameters of PM such as the dynamic international prognostic scoring system (DIPSS) for primary myelofibrosis plus score, the JAK2V617F mutation, spleen size, bone marrow reticulin fibrosis degree and use of hydroxyurea drug features. Raman spectra showed higher amounts of C-H, C-C and C-C/C-N and amide II and lower amounts of amide I and vibrations of CH groups in PM patients than in healthy ones. Furthermore, shifts of amides II and I vibrations in PM patients were noticed. Machine learning methods were used to analyze Raman regions: (i) 800 cm and 1800 cm, (ii) 1600 cm-1700 cm, and (iii) 2700 cm-3000 cm showed 100 % accuracy, sensitivity, and specificity. Differences in the spectral dynamic showed that differences in the amide II and amide I regions were the most significant in distinguishing between PM and healthy subjects. Importantly, until now, the efficacy of Raman spectroscopy has not been established in clinical diagnostics of PM disease using the correlation between Raman spectra and PM clinical prognostic scoring. Continuing, our results showed the correlation between Raman signals and bone marrow fibrosis, as well as JAKV617F. Consequently, the results revealed that Raman spectroscopy has a high potential for use in medical laboratory diagnostics to quantify multiple biomarkers simultaneously, especially in the selected Raman regions.
原发性骨髓纤维化(PM)是一种骨髓增殖性肿瘤,其特征为存在干细胞来源的克隆性肿瘤。该疾病的诊断基于体格检查、外周血检查结果、骨髓形态学、细胞遗传学及分子标志物。然而,PM的分子标志物,即JAK2V617F基因突变,在真性红细胞增多症和原发性血小板增多症等其他骨髓增殖性肿瘤中也有发现。因此,需要找到能够提供PM独特标志物的方法,以提高PM诊断的准确性,进而实现疾病的治疗。在此基础上,在本研究中,我们将拉曼光谱、主成分分析(PCA)和偏最小二乘法(PLS)分析用作PM的辅助诊断工具。为此,我们使用了从PM患者采集的血清,这些血清根据PM的临床参数进行分类,如原发性骨髓纤维化动态国际预后评分系统(DIPSS)加评分、JAK2V617F突变、脾脏大小、骨髓网状纤维增生程度以及羟基脲药物使用特征。拉曼光谱显示,与健康人相比,PM患者的C-H、C-C和C-C/C-N以及酰胺II含量更高,而酰胺I和CH基团振动含量更低。此外,还注意到PM患者酰胺II和I振动的位移。使用机器学习方法分析拉曼区域:(i)800厘米至1800厘米,(ii)1600厘米至1700厘米,以及(iii)2700厘米至3000厘米,显示出100%的准确性、敏感性和特异性。光谱动态的差异表明,酰胺II和酰胺I区域的差异在区分PM和健康受试者方面最为显著。重要的是,到目前为止,尚未通过拉曼光谱与PM临床预后评分之间的相关性来确定拉曼光谱在PM疾病临床诊断中的有效性。此外,我们的结果显示了拉曼信号与骨髓纤维化以及JAKV617F之间的相关性。因此,结果表明拉曼光谱在医学实验室诊断中具有很高的潜力,可同时对多种生物标志物进行定量分析,尤其是在选定的拉曼区域。